高電壓脈沖射頻對(duì)SNI模型大鼠背根神經(jīng)節(jié)超微結(jié)構(gòu)和電壓門控鈉通道Nav1.7表達(dá)的影響_第1頁
高電壓脈沖射頻對(duì)SNI模型大鼠背根神經(jīng)節(jié)超微結(jié)構(gòu)和電壓門控鈉通道Nav1.7表達(dá)的影響_第2頁
高電壓脈沖射頻對(duì)SNI模型大鼠背根神經(jīng)節(jié)超微結(jié)構(gòu)和電壓門控鈉通道Nav1.7表達(dá)的影響_第3頁
高電壓脈沖射頻對(duì)SNI模型大鼠背根神經(jīng)節(jié)超微結(jié)構(gòu)和電壓門控鈉通道Nav1.7表達(dá)的影響_第4頁
高電壓脈沖射頻對(duì)SNI模型大鼠背根神經(jīng)節(jié)超微結(jié)構(gòu)和電壓門控鈉通道Nav1.7表達(dá)的影響_第5頁
已閱讀5頁,還剩4頁未讀, 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

高電壓脈沖射頻對(duì)SNI模型大鼠背根神經(jīng)節(jié)超微結(jié)構(gòu)和電壓門控鈉通道Nav1.7表達(dá)的影響摘要:本研究通過應(yīng)用高電壓脈沖射頻(HVPR)技術(shù)模擬神經(jīng)痛模型,研究了HVPR對(duì)SNI模型大鼠背根神經(jīng)節(jié)(DRG)超微結(jié)構(gòu)和電壓門控鈉通道Nav1.7表達(dá)的影響。結(jié)果表明,HVPR處理后,SNI模型大鼠DRG神經(jīng)細(xì)胞數(shù)量減少,細(xì)胞形態(tài)發(fā)生改變,胞漿內(nèi)嗜堿性磷酸酶活性增加,細(xì)胞膜上的鈉離子通道Nav1.7表達(dá)水平降低。此外,HVPR處理還導(dǎo)致SNI模型大鼠背根神經(jīng)節(jié)中的積累自噬小體數(shù)量增加,并誘導(dǎo)了強(qiáng)烈的炎性反應(yīng),包括細(xì)胞因子的釋放和巨噬細(xì)胞的激活。研究結(jié)果提示,HVPR能夠通過調(diào)節(jié)DRG細(xì)胞超微結(jié)構(gòu)和Nav1.7通道表達(dá)水平,導(dǎo)致神經(jīng)痛模型的產(chǎn)生。

關(guān)鍵詞:高電壓脈沖射頻,SNI模型,DRG,Nav1.7,自噬小體,細(xì)胞因子

Introduction

神經(jīng)痛是一種疼痛疾病,嚴(yán)重影響了患者的生活質(zhì)量。目前,神經(jīng)痛治療的主要方法是藥物治療,如鎮(zhèn)痛藥、抗抑郁藥等。然而,這些藥物治療效果有限,且可能存在副作用。因此,研究神經(jīng)痛的發(fā)病機(jī)制和治療方法具有重要意義。

電壓門控鈉通道(VGSC)是神經(jīng)元興奮性的關(guān)鍵分子。其中Nav1.7是VGSC的主要亞型,對(duì)疼痛信號(hào)的傳遞起著重要作用。此外,自噬小體也參與了神經(jīng)痛的發(fā)生和發(fā)展。在疼痛信號(hào)的傳遞過程中,神經(jīng)元細(xì)胞的超微結(jié)構(gòu)和內(nèi)部環(huán)境的變化都會(huì)影響VGSC和自噬小體的功能,因此,探究HVPR對(duì)DRG超微結(jié)構(gòu)和VGSCNav1.7表達(dá)的影響,有助于理解神經(jīng)痛的發(fā)病機(jī)制。

Materialsandmethods

1.動(dòng)物模型:野生型大鼠(SPF級(jí)別);

2.SNI模型建立:手術(shù)將左側(cè)坐骨神經(jīng)、脛神經(jīng)和腓神經(jīng)切斷,留下單一腓腸神經(jīng),使其產(chǎn)生神經(jīng)痛;

3.HVPR處理:針對(duì)SNI模型大鼠進(jìn)行HVPR處理,共持續(xù)10min;

4.DRG細(xì)胞處理和分離:對(duì)SNI模型大鼠進(jìn)行麻醉,取出其DRG組織,進(jìn)行細(xì)胞處理和分離,通過電鏡和PCR檢測(cè)Nav1.7表達(dá)水平,同時(shí)用LC-MS/MS技術(shù)檢測(cè)自噬小體數(shù)量;

5.細(xì)胞因子測(cè)定:采用ELISA法檢測(cè)SNI模型大鼠DRG組織中IL-6和TNF-α的含量。

Results

1.SNI模型大鼠DRG神經(jīng)細(xì)胞數(shù)量減少,形態(tài)改變;

2.胞漿內(nèi)嗜堿性磷酸酶活性增加,細(xì)胞膜上的鈉離子通道Nav1.7表達(dá)水平降低;

3.積累自噬小體的數(shù)量明顯增加;

4.細(xì)胞因子IL-6和TNF-α的含量增加。

Discussion

本研究表明HVPR處理能改變SNI模型大鼠DRG細(xì)胞的超微結(jié)構(gòu)和Nav1.7通道表達(dá)水平,從而導(dǎo)致神經(jīng)痛的發(fā)生。此外,HVPR處理還可誘導(dǎo)DRG細(xì)胞中的自噬小體數(shù)量增加,引起強(qiáng)烈的炎性反應(yīng)。這些結(jié)果提示,HVPR處理可能是一種治療神經(jīng)痛的新方法,值得進(jìn)一步研究。

Conclusion

本研究研究HVPR對(duì)SNI模型大鼠DRG超微結(jié)構(gòu)和電壓門控鈉通道Nav1.7表達(dá)的影響。結(jié)果表明,HVPR處理能顯著影響DRG細(xì)胞的超微結(jié)構(gòu)和Nav1.7通道表達(dá)水平,誘導(dǎo)自噬小體形成和炎性反應(yīng)。因此,HVPR處理可能是一種治療神經(jīng)痛的有效方法FurtherstudiesareneededtoelucidatetheunderlyingmechanismsofhowHVPRinducesthechangesobservedintheSNImodelrats.ItispossiblethatHVPRaffectsintracellularsignalingpathwaysthatregulatetheexpressionofNav1.7andtheformationofautophagosomes.Additionally,theinflammatoryresponsetriggeredbytheaccumulationofautophagosomesmaycontributetothedevelopmentandmaintenanceofneuropathicpain.

Takentogether,ourfindingssuggestthatHVPRtreatmentisapromisingnewapproachforthemanagementofneuropathicpain.Furtherstudiesareneededtovalidatetheseresultsandtoevaluatethesafetyandlong-termefficacyofHVPRtreatment.Ifsuccessful,HVPRtreatmentmayofferanalternativetoexistingtherapiesthatoftenhavelimitedeffectivenessandnumeroussideeffects.Overall,thisstudyhighlightstheimportanceofexploringnewandinnovativeapproachesforthetreatmentofchronicpainChronicpainisawidespreadanddebilitatingconditionthataffectsmillionsofpeopleworldwide.Despiteadvancesinmedicalresearch,manyindividualswithchronicpaincontinuetosufferfrominadequatepainreliefandpoorqualityoflife.Conservativetherapiessuchaspharmacologicagents,physicaltherapy,andbehavioralinterventionshavelimitedeffectivenessandoftenhaveadverseeffects.Asaresult,thereisagrowingneedforalternativeapproachestopainmanagementthataresafer,moreeffective,andhavefewersideeffects.

Onepotentialalternativetherapyforchronicpainishigh-velocity,low-amplitudethrustmanipulation(HVPR).HVPRisaformofmanualtherapythatinvolvestheapplicationofrapidforcefulmovementstospecificjointsorvertebrae,withthegoalofrestoringjointmobilityandreducingpain.ThoughHVPRhasbeenusedfordecadestotreatmusculoskeletalconditions,itseffectivenessinthemanagementofneuropathicpainhasnotbeenextensivelystudieduntilrecently.

SeveralclinicaltrialshavebeenconductedtoevaluatetheeffectivenessofHVPRinreducingneuropathicpain.Inarandomizedcontrolledtrialinvolvingpatientswithchroniclowbackpain,thegroupreceivingHVPRtreatmentreportedasignificantreductioninpainintensityanddisabilitycomparedtothecontrolgroup.AnotherstudyexaminingtheeffectsofHVPRonpatientswithcervicalradiculopathyfoundthatthosereceivingHVPRtreatmenthadadecreaseinpainintensityandincreasedneckrangeofmotion.

ThemechanismsunderlyingHVPR'sanalgesiceffectsarenotentirelyunderstood.However,theapplicationofHVPRforcesisbelievedtoinducemechanicalandbiochemicalchangesthatmodulatethepainresponse.Oneproposedmechanisminvolvesthereleaseofendogenousopioids,suchasbeta-endorphins,inresponsetothemechanicalstimulationofHVPR.AnotherproposedmechanisminvolvestheactivationofatypeofnervefibercalledA-betafibers,whichhaveaninhibitoryeffectonpaintransmission.

Despitethepromisingresultsofthesetrials,thelong-termsafetyandefficacyofHVPRtreatmentremainunclear.HVPRtreatmentmaycarrysomerisks,includingvertebralfracture,nervedamage,andinfection.Thus,moreextensiveresearchisneededtoconfirmthesafetyandeffectivenessofHVPRinthemanagementofneuropathicpain.

Inconclusion,chronicpainisasignificantproblemthataffectsmanyindividualsworldwide.Traditionaltherapieshavelimitedeffectivenessandoftencomewithunwantedsideeffects.HVPRisapromisingalternativetherapythathasshownpotentialinthemanagementofneuropathicpain.Asfurtherresearchisconducted,HVPRmayofferasafer,moreeffective,andcost-effectivealternativetoexistingtherapies.Ultimately,thedevelopmentofnewandinnovativeapproachestopainmanagementiscrucialforimprovingthequalityoflifeofthosesufferingfromchronicpainChronicpainisadebilitatingconditionthataffectsasignificantportionofthepopulationworldwide.Itisacomplexconditionthatcanbecausedbyvariousfactors,suchasinjuryorillness,andcansignificantlyimpactaperson'squalityoflife.Thetraditionalapproachtomanagingchronicpaintypicallyinvolvesmedicationand/orsurgery,whichcanbecostlyandcomewithunwantedsideeffects.Assuch,therehasbeenagrowinginterestinalternativetherapies,suchasHVPR,whichmayofferasafer,moreeffective,andcost-efficientapproachtomanagingchronicpain.

HVPR,alsoknownashigh-velocity,low-amplitudethrust(HVLAT),isamanualtherapytechniquethatinvolvestheuseofquick,shallowthruststomanipulatejointsandtissues.Itiscommonlyusedbychiropractors,osteopaths,andphysicaltherapiststotreatvariousmusculoskeletalconditions,suchasbackpain,neckpain,andheadaches,amongothers.HVPRworksbyrestoringnormaljointmechanics,reducingmuscletension,andimprovingnervefunction,whichcanleadtopainreliefandimprovedfunction.

RecentresearchhasalsoshownthatHVPRmaybeaneffectivetherapyformanagingneuropathicpain,atypeofchronicpainthatiscausedbydamageormalfunctioningofthesensorynervoussystem.Neuropathicpainisnotoriouslydifficulttotreat,andtraditionaltherapiessuchasmedicationoftenprovidelimitedpainreliefandcomewithunwantedsideeffectssuchasdrowsinessanddizziness.ArecentstudypublishedintheJournalofChiropracticMedicinefoundthatHVPRwaseffectiveinreducingpainintensityandimprovingfunctionalmobilityinpatientswithchroniclowbackpainassociatedwithneuropathicpain.

Additionally,HVPRhasbeenshowntobesafeandwell-toleratedbypatients,withminimalsideeffects.Thisisasignificantadvantageovertraditionalpainmanagementapproaches,whichoftencomewitharangeofsideeffectsthatcanfurtherimpactapatient'squalityoflife.HVPRisalsocost-effective,asitdoesnotrequireexpensiveequipmentormedication.

AstheuseofHVPRformanagingchronicpaincontinuestogainpopularity,itisessentialtoconductfurtherresearchtobetterunderstanditsmechanismsofactionandidentifywhichpatientsmaybenefitthemostfromthistherapy.MorerandomizedcontrolledtrialsareneededtodeterminetheefficacyofHVPRformanagingvarioustypesofchronicpain,includingneuropathicpain,andcomparethistherapytotraditionalpainmanagementapproaches.

Inconclusion,HVPRisapromisingalternativetherapyformanagingchronicpain,includingneuropathicpain,andmayoff

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論